ReviewCancers2025
Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).
Bowen Zheng, Fanzhuoran Lou, Yuting He, Miao Fu, Xintian Huang, Weijuan Tan, Quan Chen, Xiaowen Xie, Tianhui Hu, Li Xiao
Abstract readReview
In one paragraphReview in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Bowen ZhengDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.ORCID 0009-0001-5773-0851 Fanzhuoran LouDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.
Yuting HeDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.
Miao FuXiamen Key Laboratory for Tumor Metastasis, Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China.
Xintian HuangDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.
Weijuan TanDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.ORCID 0000-0002-0454-3980 Quan ChenDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.
Xiaowen XieXiamen Key Laboratory for Tumor Metastasis, Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China.
Tianhui HuNational Institute for Data Science in Health and Medicine, Xiamen University, Xiamen 361102, China.ORCID 0000-0003-3998-5145 Li XiaoDepartment of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China.ORCID 0000-0002-8889-9609 Funding
Fujian Provincial Natural Science Foundation 2024J011335Medical Innovation Program of Fujian Provincial Health Commission 2023CXB006National Natural Science Foundation of China 81802640Natural Science Foundation of Fujian Province 20247011335Natural Science Foundation of Xiamen City 3502Z20227266Scientific Research Fund for Returned Overseas Chinese Students of Xiamen City 20247011335
6 · The paper itselfAbstract
Gastric cancer (GC) has a high global incidence and mortality rate [...].
Indexed as
gastric cancergastroesophageal junction cancerimmune checkpoint inhibitorspositive programmed death ligand 1
Identifiers
PMID40002252
PMCPMC11852535
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390